You are here

Tigit

TIGIT drug from iTeos shrinks lung tumors in trial

BioPharma Dive

Sun, 09/15/24 - 06:28 pm

iTeos Therapeutics

Merck stops phase 3 TIGIT trial in lung cancer for futility—and sees immune side effects again

Fierce Biotech

Thu, 08/8/24 - 11:04 am

clinical trials

BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific

Fierce Biotech

Mon, 08/5/24 - 11:10 am

Bristol Myers Squibb

bispecific antibodies

Gilead stops phase 3 TIGIT trial, doubling down on other studies and pumping $320M into partner Arcus

Fierce Biotech

Tue, 01/30/24 - 10:34 am

Gilead Sciences

Arcus Biosciences

clinical trials

Roche racks up phase 3 TIGIT win, but trial design leaves doubts

Fierce Biotech

Wed, 01/17/24 - 09:33 am

immuno-oncology

clinical trials

Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up

Fierce Biotech

Wed, 08/23/23 - 10:10 am

clinical trials

non-small cell lung cancer

Roche's closely watched immunotherapy fails key study in tough-to-treat lung cancer

BioPharma Dive

Wed, 03/30/22 - 10:54 am

clinical trials

advanced small cell lung cancer

A year of TIGIT (and Alzheimer’s) for Roche

EP Vantage

Thu, 02/3/22 - 10:53 am

Alzheimer's disease

AACR 2020 preview – no Tigit, but plenty of novel mechanisms

EP Vantage

Wed, 04/22/20 - 10:56 am

virtual meetings

Roche move endorses Iteos’s Tigit widget

EP Vantage

Tue, 03/3/20 - 10:52 am

Arcus Biosciences

iTeos Therapeutics

Roche’s next immuno-oncology combo is a big bet on Tigit

EP Vantage

Fri, 01/31/20 - 10:47 am

immuno-oncology